| Schedule of other Income |
| Schedule of other Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
April 30, |
|
|
Six Months Ended
April 30, |
|
| |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
| Revenue |
|
$ |
2,581,000 |
|
|
|
1,149,000 |
|
|
$ |
4,027,000 |
|
|
$ |
2,239,000 |
|
| Cost of goods sold |
|
|
(526,000 |
) |
|
|
(256,000 |
) |
|
|
(807,000 |
) |
|
|
(447,000 |
) |
| Salaries & consulting fees |
|
|
(839,000 |
) |
|
|
(716,000 |
) |
|
|
(1,562,000 |
) |
|
|
(1,425,000 |
) |
| Professional fees |
|
|
(295,000 |
) |
|
|
(137,000 |
) |
|
|
(455,000 |
) |
|
|
(283,000 |
) |
| Commissions |
|
|
(279,000 |
) |
|
|
(91,000 |
) |
|
|
(465,000 |
) |
|
|
(178,000 |
) |
| Marketing |
|
|
(238,000 |
) |
|
|
(73,000 |
) |
|
|
(342,000 |
) |
|
|
(114,000 |
) |
| Stock based compensation |
|
|
(590,000 |
) |
|
|
(1,096,000 |
) |
|
|
(1,182,000 |
) |
|
|
(2,187,000 |
) |
| Lab expenses |
|
|
(204,000 |
) |
|
|
(39,000 |
) |
|
|
(373,000 |
) |
|
|
(41,000 |
) |
| Research & development |
|
|
(31,000 |
) |
|
|
(42,000 |
) |
|
|
(50,000 |
) |
|
|
(48,000 |
) |
| Insurance |
|
|
(47,000 |
) |
|
|
(80,000 |
) |
|
|
(109,000 |
) |
|
|
(106,000 |
) |
| Office expenses & other |
|
|
(45,000 |
) |
|
|
(13,000 |
) |
|
|
(72,000 |
) |
|
|
(57,000 |
) |
| Other income (expenses), net |
|
|
(22,000 |
) |
|
|
3,000 |
|
|
|
3,000 |
|
|
|
13,000 |
|
| Gain on sale of Exotropin interests |
|
|
390,000 |
|
|
|
- |
|
|
|
390,000 |
|
|
|
- |
|
| Net loss |
|
$ |
(145,000 |
) |
|
$ |
(1,391,000 |
) |
|
$ |
(997,000 |
) |
|
$ |
(2,634,000 |
) |
|